China SXT Pharmaceuticals SXTC

$ 0.47 -11.3%

Annual report 2024
added 10-19-2024

China SXT Pharmaceuticals Balance Sheet 2011-2024 | SXTC

Annual Balance Sheet China SXT Pharmaceuticals

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-13.4 M	-563 K	-8.83 M	-175 K	237 K	-	-	-	-	-	-
Long Term Debt	117 K	118 K	-	6.29 K	36.5 K	41.7 K	-	-	-	-	-	-	-	-
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	295 K	366 K	-	6.29 K	36.5 K	41.7 K	-	-	-	-	-	-	-	-
Total Current Liabilities	8.9 M	14.5 M	17.1 M	18.6 M	12.3 M	6.32 M	-	-	-	-	-	-	-	-
Total Liabilities	9.2 M	14.9 M	17.1 M	18.6 M	12.3 M	6.36 M	4.37 M	3.58 M	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	586 K	-	-	-	-	-	-
Retained Earnings	-24.7 M	-21.6 M	-15.7 M	-9.95 M	-7.2 M	3.08 M	1.54 M	357 K	-	-	-	-	-	-
Total Assets	23.1 M	29.6 M	33.5 M	34.5 M	21.7 M	17.5 M	7.66 M	5.43 M	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	13.4 M	7.29 M	9.13 M	658 K	65.6 K	-	-	-	-	-	-
Book Value	13.9 M	14.7 M	16.4 M	16 M	9.4 M	11.1 M	3.29 M	1.85 M	-	-	-	-	-	-
Total Shareholders Equity	13.9 M	14.7 M	16.4 M	16 M	9.4 M	11.1 M	3.29 M	1.85 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet China SXT Pharmaceuticals

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	6.29 K	-	15.2 K	-	36.5 K	-	55.1 K	-	41.7 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	6.29 K	-	15.2 K	-	36.5 K	-	873 K	-	41.7 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	17.1 M	-	8.88 M	-	18.6 M	-	5.52 M	-	12.3 M	-	11.6 M	-	6.36 M	-	-	-	4.37 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-15.7 M	-	-13 M	-	-9.95 M	-	-5.82 M	-	-7.2 M	-	736 K	-	3.08 M	-	-	-	1.54 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	33.5 M	-	22.7 M	-	34.5 M	-	24 M	-	21.7 M	-	23 M	-	17.5 M	-	-	-	7.66 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	15.5 M	-	31.3 K	-	13.3 M	-	10.4 M	-	7.29 M	-	8.25 M	-	9.29 M	-	384 K	-	658 K	-	-	-	65.6 K	-	-	-	11.4 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	16.4 M	-	13.8 M	-	16 M	-	18.5 M	-	9.4 M	-	11.4 M	-	11.1 M	-	-	-	3.29 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	16.4 M	-	13.8 M	-	16 M	-	18.5 M	-	9.4 M	-	11.4 M	-	11.1 M	-	4.6 M	-	3.29 M	-	-	-	1.85 M	-	-	-	743 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency